Drug intelligence / Profile preview

JPT-0008

Development stage: Unknown
Lead developer: J-Pharma
Modality: Small Molecules
Administration: Oral

Overview

JPT-0008 is an orally bioavailable small molecule inhibitor of the L-type amino acid transporter 1 (LAT1, also known as SLC7A5), currently under development by J-Pharma. LAT1 is a sodium-independent amino acid transporter that is frequently overexpressed in various cancers to support the high metabolic demand for essential amino acids required for rapid cell proliferation. By selectively inhibiting LAT1, JPT-0008 aims to disrupt the nutrient supply to tumor cells, thereby inhibiting cell growth and inducing apoptosis. As of early 2025, the program is in Phase 1 clinical development, although specific primary indications have not yet been publicly disclosed.

Targets

SLC7A5 (Large neutral amino acid transporter small subunit 1)

Beyond the preview

Go deeper on JPT-0008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JPT-0008.

Explore the full profile